Assessment of contribution of BCRP to intestinal absorption of various drugs using portal‐systemic blood concentration difference model in mice
Authors:
Open Access
- 17 January 2020
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 8 (1) , e00544
Abstract
Prediction of the intestinal absorption of new chemical entities (NCEs) is still difficult, in part because drug efflux transporters, including breast cancer resistance protein (BCRP) and P‐glycoprotein (P‐gp), restrict their intestinal permeability. We have demonstrated that the absorptive quotient (AQ) obtained from the in vitro Caco‐2 permeability study would be a valuable parameter for estimating the impact of BCRP on the intestinal absorption of drugs. In this study, in order to assess the correlation between the in vitro AQ for BCRP and in vivo contribution of BCRP on drug absorption, we evaluated the oral absorption of various compounds by portal‐systemic blood concentration (P‐S) difference method in wild‐type (WT), Bcrp(−/−), and Mdr1a/1b(−/−) mice. In addition, we also calculated a rate of BCRP contribution (Rbcrp). Ciprofloxacin and nitrofurantoin showed the low Rbcrp value (0.05 and 0.15), and their apparent fractions of intestinal absorption in WT mice were 46.5% and 63.7%, respectively. These results suggest that BCRP hardly affects their intestinal absorption in mice. On the other hand, the apparent fraction of intestinal absorption of topotecan and sulfasalazine was significantly lower in WT mice than in Bcrp(−/−) mice. Moreover, their Rbcrp values were 0.42 and 0.79, respectively, indicating the high contribution of BCRP to their oral absorption. Furthermore, in vivo Rbcrp calculated in this study was almost comparable to in vitro AQ obtained from Caco‐2 permeability study. This study provides useful concepts in assessing the contribution of BCRP on intestinal absorption in drug discovery and development process.Keywords
Funding Information
- Ritsumeikan University
This publication has 35 references indexed in Scilit:
- Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of PhytoestrogensMolecular Pharmacology, 2007
- Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell LinesDrug Metabolism and Disposition, 2007
- Involvement of BCRP (ABCG2) in the Biliary Excretion of PitavastatinMolecular Pharmacology, 2005
- The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic NitrofurantoinMolecular Pharmacology, 2005
- Characterization of Polarized Expression of Point- or Deletion-Mutated Human BCRP/ABCG2 in LLC-PK1 CellsPharmaceutical Research, 2005
- The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.2003
- The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyriaProceedings of the National Academy of Sciences, 2002
- Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerizationInternational Journal of Cancer, 2001
- Correlation of Gene Expression of Ten Drug Efflux Proteins of the ATP-Binding Cassette Transporter Family in Normal Human Jejunum and in Human Intestinal Epithelial Caco-2 Cell MonolayersThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Method to Estimate the Rate and Extent of Intestinal Absorption in Conscious Rats Using an Absorption Probe and Portal Blood SamplingPharmaceutical Research, 1995